Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3380 - Mutant KIT Translocates into the Nucleus and Induces NFKBIB Expression that Leads to KIT Expression in Imatinib-Resistant Gastrointestinal Stromal Tumors.

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Translational Research;  GIST

Presenters

Yuan-Shuo Hsueh

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

Y. Hsueh1, H.H. Chang2, Y. Shan3, H..S. Sun4, J.A. Fletcher5, C. Li6, L. Chen1

Author affiliations

  • 1 National Institute Of Cancer Research, National Health Research Institutes, 704 - Tainan/TW
  • 2 Institute Of Clinical Pharmacy And Pharmaceutical Sciences, College Of Medicine, National Cheng Kung University, Tainan, Taiwan, 701 - Tainan/TW
  • 3 Department Of Surgery, National Cheng Kung University Hospital, 704 - Tainan/TW
  • 4 Institute Of Molecular Medicine, College Of Medicine, National Cheng Kung University, 701 - Tainan/TW
  • 5 Department Of Pathology, Brigham and Women’s Hospital and Harvard Medical School, 02115 - Boston/US
  • 6 Department Of Pathology, Chi-Mei Foundation Medical Center, 710 - Tainan/TW
More

Resources

Abstract 3380

Background

Gastrointestinal stromal tumor (GIST) is a dominantly mutant KIT-driven tumor. Prolonged tyrosine kinase inhibitor (TKI) treatment may result in a resistant phenotype through acquired secondary KIT mutation. Increasing evidences show that membrane-bound receptors, as EGFR, can translocate into the nucleus, mediate genes expression, and lead to tumor survival and drug resistance. However, it’s barely known the nuclear role of KIT in GIST.

Methods

In this study, two imatinib (IM)-resistant GIST cell lines, GIST48 and GIST430, were used as a model.

Results

In this study, we first showed that KIT is distributed both in the cytoplasm and the nucleus in IM-resistant GIST cells. Using ChIP-seq and ChIP assay, we identified that nuclear KIT bound to the NFKBIB promoter region and regulated its expression. The expression levels of NFKBIB and phosopho-KIT were significantly correlated with NCCN-risk category in surgically resected GISTs stained by immunohistochemistry. The cell viabilities were inhibited as accompanying with KIT reduction in GIST cells while NFKBIB was silenced or RELA was overexpressed. Moreover, RELA was activated, translocated into the nucleus, and bound to KIT promoter region in NFKBIB-silenced or RELA-overexpressed GIST cells. Valproic acid, acted as a NFKB inducer, could induce RELA nucleus translocation and binding to KIT promoter region that led to the reduction of protein and RNA expression level of KIT and the cell viabilities of GIST cells. Furthermore, the combination of IM with low-dose valproic acid showed synergistically inhibitory effect on cell viabilities of GIST cells and comparable effects on reducing phospho-KIT level and inhibiting tumor growth as high-dose valproic acid did in GIST430 xenograft model.

Conclusions

Taken together, we first demonstrated that phosphorylated KIT could translocate into the nucleus and drive itself expression in IM-resistant GIST cells through mediating NFKBIB expression. In addition, our findings identified a novel and druggable KIT-NFKBIB-NFKB regulatory axis that provides a new insight on tumorigenesis and therapeutic option for IM-resistant, mutant KIT-expressing GISTs.

Clinical trial identification

Legal entity responsible for the study

National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

Funding

National Health Research Institutes, Taiwan and the Ministry of Science and Technology, Taiwan.

Disclosure

Y-S. Hsueh: Research funds were provided by the Ministry of Science and Technology, Taiwan. L-T. Chen: Research funds were provided by the National Health Research Institutes, Taiwan. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.